XML 48 R40.htm IDEA: XBRL DOCUMENT

Share Capital (Tables)

12 Months Ended

Dec. 31, 2019

Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]

Share capital is composed as follows:


	Issued and outstanding Number of shares December 31,
	2019	2018
Ordinary shares no par value	99,528,435	93,254,185

Schedule of Fair Value Assumptions Used for All Equity Based Awards Estimated Using Black-Scholes Option Pricing Model

The fair value of share-based awards was estimated using the Black-Scholes model for all equity grants. For market condition awards, the Company also applied the Monte-Carlo simulation model, with the following underlying assumptions:


	Year ended December 31,
	2019		2018		2017
Stock Option Plans
Expected term (years)	5.50-6.00		5.50-6.25		5.50-6.25
Expected volatility	55%-61%		52%-55%		57%-59%
Risk-free interest rate	1.73%-2.40%		2.70%-2.99%		1.97%-2.23%
Dividend yield	0.00	%	0.00	%	0.00	%
ESPP
Expected term (years)	0.50		0.50		0.50
Expected volatility	44%-62%		45%-53%		76%-82%
Risk-free interest rate	2.10%-2.51%		1.61%-2.14%		0.62%-1.13%
Dividend yield	0.00	%	0.00	%	0.00	%

Schedule of Stock Options to Purchase Ordinary Shares

A summary of the status of the Company’s options to purchase ordinary shares as of December 31, 2019 and changes during the year ended on that date is presented below:


	Year ended December 31, 2019
	Number of options	Weighted average exercise price		Aggregate intrinsic value
Outstanding at beginning of year	14,438,215	$	13.56
Granted	1,552,987	50.45
Exercised	(5,466,170)	10.83
Forfeited and cancelled	(174,222)	22.11
Outstanding at end of year	10,350,810	$	20.40	$	661,150
Exercisable options	3,217,923	$	15.55	$	221,146

Schedule of RSUs

A summary of the status of the Company’s RSUs as of December 31, 2019 and changes during the year ended on that date is presented below:


	Year ended December 31, 2019
	Number of RSUs	Weighted average grant date fair value price		Aggregate intrinsic value
Unvested at beginning of year	1,613,197	$	14.04
Granted	634,694	52.28
Vested	(740,714)	13.47
Forfeited and cancelled	(32,782)	37.84
Unvested at end of year	1,474,395	$	30.26	$	124,247

Schedule of Equity-Based Compensation Expenses Related to Company's Equity-Based Awards

The total equity-based compensation expense related to all of the Company’s equity-based awards recognized for the years ended December 31, 2019, 2018 and 2017, was comprised as follows:


	Year ended December 31,
	2019		2018		2017
Cost of revenues	$	2,231	$	1,261	$	467
Research, development and clinical trials	7,570		4,709		3,587
Sales and marketing	11,897		7,393		3,784
General and administrative	30,718		26,483		19,278
Total share-based compensation expense	$	52,416	$	39,846	$	27,116

Schedule of Stock Option Outstanding

The options outstanding as of December 31, 2019 are as follows:


Exercise price	Number of options outstanding	Weighted average remaining contractual term	Number of options exercisable	Weighted average remaining contractual term
$		(years)		(years)
0.23 - 10.00	2,256,916	6.15	984,380	4.87
10.01 - 20.00	3,205,758	6.83	869,058	5.84
20.01 - 30.00	2,933,518	7.4	1,225,951	6.57
30.01 - 40.00	424,414	8.56	138,534	8.47
40.01 - 50.00	1,347,064	9.29	—	—
50.01 - 60.00	44,380	9.39	—	—
60.01 - 90.00	138,760	9.7	—	—
	10,350,810	7.28	3,217,923	5.94